Prediction of functional outcome 18 months after a first psychotic episode: A proton magnetic resonance spectroscopy study

Archives of General Psychiatry

Volumn 63, Issue 9, 2006, Pages 969-976

  Wood, Stephen J ^a,b   Berger, Gregor E ^c   Lambert, Martin ^c   Conus, Phillipe ^c   Velakoulis, Dennis ^a   Stuart, Geoffrey W ^a   Desmond, Patricia ^d   McGorry, Patrick D ^c   Pantelis, Christos ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c ORYGEN RESEARCH CENTRE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; N ACETYLASPARTIC ACID;

ADOLESCENT; ADULT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; GRAY MATTER; HOSPITAL ADMISSION; HUMAN; MALE; OUTCOME ASSESSMENT; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SPECTROSCOPY; WHITE MATTER;

ADULT; ASPARTIC ACID; CHOLINE; CREATINE; FEMALE; FOLLOW-UP STUDIES; FUNCTIONAL LATERALITY; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT READMISSION; PHOSPHOCREATINE; PREDICTIVE VALUE OF TESTS; PREFRONTAL CORTEX; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 33748314539     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.9.969     Document Type: Article

References (79)

1. Carpenter WT Jr, Strauss JS. The prediction of outcome in schizophrenia, IV: eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis. 1991;179:517-525.
2. Thara R, Henrietta M, Joseph A, Rajkumar S, Eaton WW. Ten-year course of schizophrenia: the Madras longitudinal study. Acta Psychiatr Scand. 1994;90:329-336.
3. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001;178:506-517.
4. Henry LP, Harris MG, Schwartz OS, et al. The 8 year functional and symptomatic outcome of first episode psychosis (FEP) [abstract]. Schizophr Bull. 2005;31:224.
5. May PR, Van Putten T, Yale C. Predicting outcome of antipsychotic drug treatment from early response. Am J Psychiatry. 1980;137:1088-1089.
6. Van Putten T, May PR. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry. 1978;35:477-480.
7. Thompson KN, McGorry PD, Harrigan SM. Recovery style and outcome in first-episode psychosis. Schizophr Res. 2003;62:31-36.
8. Verdoux H, Liraud F, Assens F, Abalan F, van Os J. Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients. Schizophr Res. 2002;56:149-159.
9. Goldman M, Tandon R, DeQuardo JR, Taylor SF, Goodson J, McGrath M. Biological predictors of 1-year outcome in schizophrenia in males and females. Schizophr Res. 1996;21:65-73.
10. Beiser M, Bean G, Erickson D, Zhang J, Iacono WG, Rector NA. Biological and psychosocial predictors of job performance following a first episode of psychosis. Am J Psychiatry. 1994;151:857-863.
11. Johnstone EC, Macmillan JF, Frith CD, Benn DK, Crow TJ. Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry. 1990;157:182-189.
12. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
13. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003.
14. Malla AK, Norman RM, Manchanda R, Ahmed MR, Scholten D, Harricharan R, Cortese L, Takhar J. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res. 2002;54:231-242.
15. Murray RM, van Os J. Predictors of outcome in schizophrenia. J Clin Psychopharmacol. 1998;18(suppl 1):2S-4S.
16. Altamura AC, Bassetti R, Sassella F, Salvadori D, Mundo E. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res. 2001;52:29-36.
17. Larsen TK, Moe LC, Vibe-Hansen L, Johannessen JO. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res. 2000;45:1-9.
18. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003;33:97-110.
19. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res. 2001;49:1-52.
20. Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000; 157:16-25.
21. Staal WG, Hulshoff Pol HE, Kahn RS. Outcome of schizophrenia in relation to brain abnormalities. Schizophr Bull. 1999;25:337-348.
22. Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson M, Eiser A, Goldman M. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res. 2000;45:191-201.
23. Williams AO, Reveley MA, Kolakowska T, Ardern M, Mandelbrote BM. Schizophrenia with good and poor outcome, II: cerebral ventricular size and its clinical significance. Br J Psychiatry. 1985;146:239-246.
24. Wilms G, van Ongeval C, Baert AL, Claus A, Bollen J, de Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S. Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients. Acta Psychiatr Scand. 1992;85:306-312.
25. Milev P, Ho BC, Arndt S, Nopoulos P, Andreasen NC. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up. Biol Psychiatry. 2003;54:608-615.
26. van Haren NEM, Cahn W, Hulshoff Pol HE, Schnack HG, Caspers E, Lemstra A, Sitskoorn MM, Wiersma D, van den Bosch RJ, Dingemans PM, Schene AH, Kahn RS. Brain volumes as predictor of outcome in recent-onset schizophrenia: a multicenter MRI study. Schizophr Res. 2003;64:41-52.
27. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain. 1999;122(pt 4):593-624.
28. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 1993;13:981-989.
29. Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem. 2000;74:254-262.
30. 1H-NMR spectroscopic studies of the brain. Neurosci Biobehav Rev. 1989;13:23-31.
31. Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings: part II. Biol Psychiatry. 2000;48:369-380.
32. Bertolino A, Esposito G, Callicott JH, Mattay VS, van Horn JD, Frank JA, Berman KF, Weinberger D. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiatry. 2000;157:26-33.
33. Stanley JA, Williamson PC, Drost D, Rylett RJ, Carr TJ, Malla A, Thompson RT. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull. 1996;22:597-609.
34. Callicott JH, Bertolino A, Egan M, Mattay VS, Langheim FJP, Weinberger DR. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry. 2000;157:1646-1651.
35. Bertolino A, Sciota D, Brudaglio F, Altamura M, Blasi G, Bellomo A, Antonucci N, Callicott JH, Goldberg TE, Scarabino T, Weinberger DR, Nardini M. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatry. 2003;160:483-489.
36. Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD, Yung AR, Desmond P, Pantelis C. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull. 2003;29:831-843.
37. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996; 22:305-326.
38. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
39. White L, Harvey PD, Opler L, Lindenmayer JP. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: a multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. Psychopathology. 1997;30:263-274.
40. Stuart GW, Smith D, Pantelis C. Syndromes of psychosis and the Positive and Negative Syndrome Scale (PANSS): lack of support for the three-syndrome model of psychotic symptoms [abstract]. Schizophr Res. 2001;49(suppl 1):23.
41. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-679.
42. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112:141-148.
43. McGorry PD, Singh BS, Copolov DL, Kaplan I, Dossetor CR, van Riel RJ. Royal Park Multidiagnostic Instrument for Psychosis: part II: development, reliability, and validity. Schizophr Bull. 1990;16:517-536.
44. McGorry PD, Copolov DL, Singh BS. Royal Park Multidiagnostic Instrument for Psychosis: part I: rationale and review. Schizophr Bull. 1990;16:501-515.
45. McGorry PD. Evaluating the importance of reducing the duration of untreated psychosis. Aust N Z J Psychiatry. 2000;34(suppl):S145-S149.
46. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
47. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, Md: National Institute of Mental Health; 1976. DHEW publication (ADM) 76-338.
48. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB; SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;(416):16-23.
49. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159-171.
50. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:470-484.
51. Tohen M, Hennen J, Zarate C Jr, Baldessarini RJ, Strakowski SM, Stoll AL, Faedda GL, Suppes T, Gebre-Medhin P, Cohen BM. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220-228.
52. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
53. Jaccard J, Turrisi R, Wan CK. Interaction Effects in Multiple Regression. Newbury Park, Calif: Sage Publications; 1990.
54. Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, Zipursky R, Strakowski S, Sharma T, Kahn R, Gur R, Tollefson G; HGDH Research Group. Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry. 2004;185:18-24.
55. Singh SP, Burns T, Amin S, Jones PB, Harrison G. Acute and transient psychotic disorders: precursors, epidemiology, course and outcome. Br J Psychiatry. 2004;185:452-459.
56. Siegel SJ, Irani F, Brensinger CM, Kohler CG, Bilker WB, Ragland JD, Kanes SJ, Gur RC, Gur RE. Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry. 2006;163:433-441.
57. Sigmundsson T, Maier M, Toone BK, Williams SC, Simmons A, Greenwood K, Ron MA. Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res. 2003;64:63-71.
58. Pantelis C, Stuart GW, Nelson HE, Robbins TW, Barnes TRE. Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. Am J Psychiatry. 2001;158:1276-1285.
59. Molina V, Sánchez J, Reig S, Sanz J, Benito C, Santamarta C, Pascau J, Sarramea F, Gispert JD, Misiego JM, Palomo T, Desco M. N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr Res. 2005;73:209-219.
60. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry. 2005;162:71-78.
61. Wood SJ, Pantelis C, Proffitt T, Phillips LJ, Stuart GW, Buchanan JA, Mahony K, Brewer W, Smith DJ, McGorry PD. Spatial working memory ability is a marker of risk-for-psychosis. Psychol Med. 2003;33:1239-1247.
62. Velakoulis D, Pantelis C, McGorry PD, Dudgeon P, Brewer W, Cook M, Desmond P, Bridle N, Tierney P, Murrie V, Singh B, Copolov D. Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. Arch Gen Psychiatry. 1999;56:133-140.
63. Hirayasu Y, Shenton ME, Salisbury DF, Dickey CC, Fischer IA, Mazzoni P, Kisler T, Arakaki H, Kwon JS, Anderson JE, Yurgelun-Todd D, Tohen M, McCarley RW. Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry. 1998;155:1384-1391.
64. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, Yung AR, Bullmore ET, Brewer W, Soulsby B, Desmond P, McGuire PK. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361:281-288.
65. Velakoulis D, Wood SJ, Wong MTH, McGorry PD, Yung AR, Phillips LJ, Smith D, Brewer W, Proffitt T, Desmond P, Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry. 2006;63:139-149. Medline 16461856.
66. 13C] glucose infusion. J Neurochem. 2001;77:347-350.
67. Baslow MH. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res. 2003;28:941-953.
68. Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen RW. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem. 2001;78:736-745.
69. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology. 2002;27:672-683.
70. Gorman JM, Yurgelun-Todd D, Chang L, Tang CY, Bertolino A. Magnetic resonance spectroscopy: recent findings in understanding the neurochemistry of schizophrenia [abstract]. Schizophr Bull. 2005;31:443.
71. Ke Y, Coyle JT, Simpson NS, Gruber SA, Renshaw PF, Yurgelun-Todd D. Frontal brain NAA T2 values are significantly lower in schizophrenia [abstract]. Schizophr Res. 2003;60:242.
72. Lambert M, Holzbach R, Moritz S, Postel N, Krausz M, Naber D. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Int Clin Psychopharmacol. 2003;18:251-260.
73. Kivircik Akdede BB, Alptekin K, Kitis A, Arkar H, Akvardar Y. Effects of quetiapine on cognitive functions in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:233-238.
74. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156:990-999.
75. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M; HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62:361-370.
76. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004;161:985-995.
77. 2) of the proton MRS creatine resonance in human brain. Magn Reson Med. 2002;47:232-238.
78. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 2003;60:585-594.
79. Wood SJ, Velakoulis D, Smith D, Bond D, Stuart GW, McGorry PD, Brewer WJ, Bridle N, Eritaia J, Desmond P, Singh B, Copolov D, Pantelis C. A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophr Res. 2001;52:37-46.